Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Glucocorticoid-induced osteoporosis].

Shigemitsu Yasuda1, Masakazu Kogawa, Seiki Wada

  • 1Fourth Department of Internal Medicine, Saitama Medical School.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 18, 2003
PubMed
Summary

Glucocorticoid-induced osteoporosis, a common complication, causes rapid bone loss. Amino-bisphosphonates like alendronate effectively increase bone density and reduce fracture risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On-treatment change in bone turnover markers predicts 2-year bone mineral density after sequential therapy following romosozumab: a real-world cohort study.

Frontiers in endocrinology·2026
Same author

Context-Dependent Association Between Serum 25-Hydroxyvitamin D and Romosozumab Bone Mineral Density Response: A Stratified Analysis by Renal Function Category and Prior Treatment History in a Real-World Japanese Cohort.

Nutrients·2026
Same author

Romosozumab Achieves Consistent Lumbar Spine BMD Gains Across All BMI Categories: The Apparent Enhanced Response in Underweight Patients is a Mathematical Artifact of Percentage Change.

Calcified tissue international·2026
Same author

Prior treatment, not vitamin D, predicts romosozumab response in 314 osteoporosis patients: A retrospective cohort study.

Bone reports·2026
Same author

The Preoperative Anterior Pelvic Plane Angle Predicts Cup Anteversion Changes at 1 Year after Total Hip Arthroplasty.

Acta medica Okayama·2026
Same author

Acquired Osteomalacia Associated with Autoantibodies against PHEX.

The New England journal of medicine·2025

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Context:

  • Glucocorticoid therapy, especially at doses of 7.5 mg/day or higher, is a significant risk factor for osteoporosis.
  • Bone loss accelerates within the first six months of glucocorticoid treatment.
  • Mechanisms include suppressed bone formation and increased bone resorption, exacerbated by hypogonadism.

Purpose:

  • To evaluate the efficacy of novel amino-bisphosphonates in managing glucocorticoid-induced osteoporosis.
  • To compare the effectiveness of bisphosphonates against existing therapies like estrogen, vitamin D, and calcitonin.

Summary:

  • Glucocorticoid-induced osteoporosis is a serious complication of long-term steroid use.
  • Amino-bisphosphonates, including alendronate and risedronate, demonstrate significant improvements in bone mineral density.
  • These agents effectively prevent and treat glucocorticoid-induced osteoporosis, reducing fracture incidence.

Impact:

  • Amino-bisphosphonates offer a superior therapeutic strategy for glucocorticoid-induced osteoporosis.
  • Improved bone mineral density and reduced fracture risk enhance patient outcomes.
  • This research provides a basis for updated clinical guidelines in managing steroid-induced bone loss.

Related Experiment Videos